Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 223 |
| CEO | Martin Babler |
Contact Details
Address: 280 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 231 6625 |
| Website | alumis.com |
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1847367 |
| CUSIP Number | 022307102 |
| ISIN Number | US0223071020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Roy C. Hardiman J.D. | Chief Business and Strategy Officer |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sanam Pangali J.D. | Chief Legal Officer and Corporate Secretary |
| Claire Langrish Ph.D. | Senior Vice President and Head of Immunology and Translational Science |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology and Project Team Leader |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| Mark Bradley | Chief Development Officer |
| Kolbot By Ph.D. | Senior Vice President and Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 19, 2026 | 10-K | Annual Report |
| Mar 19, 2026 | 8-K | Current Report |
| Jan 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 13, 2026 | SCHEDULE 13D/A | Filing |
| Jan 12, 2026 | SCHEDULE 13D/A | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 424B5 | Filing |
| Jan 6, 2026 | 424B5 | Filing |
| Jan 6, 2026 | 8-K | Current Report |